Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Company Overview - Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics aimed at improving survival and overall well-being through a precision oncology approach [5]. Offering Details - Enliven has priced its public offering of 8,394,737 shares of common stock at $19.66 per share, with an option for investors to purchase pre-funded warrants for an additional 1,780,263 shares at $19.659 each [1]. - The gross proceeds from the offering are expected to be approximately $200 million before deducting underwriting discounts and commissions [1]. - The offering is expected to close on or about June 16, 2025, subject to customary closing conditions [1]. - Enliven has granted underwriters a 30-day option to purchase up to an additional 1,526,250 shares at the public offering price [1]. Underwriters - Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho are acting as joint book-running managers for the offering, with LifeSci Capital serving as the lead manager [2]. Regulatory Compliance - The offering is being made pursuant to a Registration Statement on Form S-3, which has been filed with and declared effective by the SEC [3]. - A final prospectus supplement and accompanying prospectus will be filed with the SEC [3]. Strategic Focus - Enliven aims to address unmet medical needs with a focus on developing potentially first-in-class or best-in-class therapies through insights in clinically validated biological targets and differentiated chemistry [5].